Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Olema Pharmaceuticals, Inc. - Common Stock
(NQ:
OLMA
)
4.600
-0.070 (-1.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Olema Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
February 22, 2023
Via
Benzinga
Olema Oncology to Participate at Upcoming Investor Conferences
February 21, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Pharma Says Lead Candidate Robust Activity In Breast Cancer Patients
October 26, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 12, 2023
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Olema Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 07, 2022
Via
Benzinga
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
December 07, 2022
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
November 21, 2022
From
Olema Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 15, 2022
Via
Benzinga
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present at Upcoming Investor Conferences in November
November 01, 2022
From
Olema Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 31, 2022
Gainers PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million.
Via
Benzinga
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
October 26, 2022
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
From
Olema Oncology
Via
GlobeNewswire
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
October 21, 2022
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 10, 2022
We're starting off the trading week with a look at the biggest pre-market stock movers for Monday morning and the news moving them!
Via
InvestorPlace
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Olema Oncology
Via
GlobeNewswire
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
August 09, 2022
Via
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
August 11, 2022
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Via
Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
July 25, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 21, 2022
Via
Benzinga
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
July 22, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...
Via
Benzinga
Olema Oncology Shares Ascend As FDA Grants Fast Track Status To Breast Cancer Candidate
July 21, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Olema Oncology’s (NASDAQ: OLMA) lead asset OP-1250 for the treatment of ER-positive (ER+), human epidermal growth...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.